Beta-trace protein in chronic inflammatory demyelinating polyradiculoneuropathy and Guillain-Barré syndrome – clinical utilization and a new insight into pathophysiological mechanisms

BTP in CSF and plasma may be a potential biomarker to aid in the diagnosis of CIDP. BTP in CSF could be a potentially more informative biomarker than albumin in a subgroup of patients with GBS and CIDP who have a normal or mildly elevated Q.alb. BTP in CSF may be predictive for therapy response in patient with CIDP, but needs to be validated in larger studies.